Brendan M Everett1, Jeffrey S Berger2, JoAnn E Manson3, Paul M Ridker4, Nancy R Cook3. 1. Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: beverett@partners.org. 2. Division of Cardiovascular Medicine and Hematology, Department of Medicine and the Division of Vascular Surgery, Department of Surgery, New York University School of Medicine, New York, New York. 3. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 4. Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Although N-terminal pro-B-type natriuretic peptide (NT-proBNP) has a strong relationship with incident cardiovascular disease (CVD), few studies have examined whether NT-proBNP adds to risk prediction algorithms, particularly in women. OBJECTIVES: This study sought to evaluate the relationship between NT-proBNP and incident CVD in women. METHODS: Using a prospective case-cohort within the WHI (Women's Health Initiative) observational study, we selected 1,821 incident cases of CVD (746 myocardial infarctions, 754 ischemic strokes, 160 hemorrhagic strokes, and 161 other cardiovascular [CV] deaths) and a randomly selected reference cohort of 1,992 women without CVD at baseline. RESULTS: Median levels of NT-proBNP were higher at study entry among incident cases (120.3 ng/l [interquartile range (IQR): 68.1 to 219.5 ng/l]) than among control subjects (100.4 ng/l [IQR: 59.7 to 172.6 ng/l]; p < 0.0001). Women in the highest quartile of NT-proBNP (≥140.8 ng/l) were at 53% increased risk of CVD versus those in the lowest quartile after adjusting for traditional risk factors (1.53 [95% confidence interval (CI): 1.21 to 1.94]; p for trend <0.0001). Similar associations were observed after adjustment for Reynolds Risk Score covariables (1.53 [95% CI: 1.20 to 1.95]; p for trend <0.0001); the association remained in separate analyses of CV death (2.66 [95% CI: 1.48 to 4.81]; p for trend <0.0001), myocardial infarction (1.39 [95% CI: 1.02 to 1.88]; p for trend = 0.008), and stroke (1.60 [95% CI: 1.22 to 2.11]; p for trend <0.0001). When added to traditional risk covariables, NT-proBNP improved the c-statistic (0.765 to 0.774; p = 0.0003), categorical net reclassification (0.08; p < 0.0001), and integrated discrimination (0.0105; p < 0.0001). Similar results were observed when NT-proBNP was added to the Reynolds Risk Score. CONCLUSIONS: In this multiethnic cohort of women with numerous CV events, NT-proBNP modestly improved measures of CVD risk prediction.
BACKGROUND: Although N-terminal pro-B-type natriuretic peptide (NT-proBNP) has a strong relationship with incident cardiovascular disease (CVD), few studies have examined whether NT-proBNP adds to risk prediction algorithms, particularly in women. OBJECTIVES: This study sought to evaluate the relationship between NT-proBNP and incident CVD in women. METHODS: Using a prospective case-cohort within the WHI (Women's Health Initiative) observational study, we selected 1,821 incident cases of CVD (746 myocardial infarctions, 754 ischemic strokes, 160 hemorrhagic strokes, and 161 other cardiovascular [CV] deaths) and a randomly selected reference cohort of 1,992 women without CVD at baseline. RESULTS: Median levels of NT-proBNP were higher at study entry among incident cases (120.3 ng/l [interquartile range (IQR): 68.1 to 219.5 ng/l]) than among control subjects (100.4 ng/l [IQR: 59.7 to 172.6 ng/l]; p < 0.0001). Women in the highest quartile of NT-proBNP (≥140.8 ng/l) were at 53% increased risk of CVD versus those in the lowest quartile after adjusting for traditional risk factors (1.53 [95% confidence interval (CI): 1.21 to 1.94]; p for trend <0.0001). Similar associations were observed after adjustment for Reynolds Risk Score covariables (1.53 [95% CI: 1.20 to 1.95]; p for trend <0.0001); the association remained in separate analyses of CV death (2.66 [95% CI: 1.48 to 4.81]; p for trend <0.0001), myocardial infarction (1.39 [95% CI: 1.02 to 1.88]; p for trend = 0.008), and stroke (1.60 [95% CI: 1.22 to 2.11]; p for trend <0.0001). When added to traditional risk covariables, NT-proBNP improved the c-statistic (0.765 to 0.774; p = 0.0003), categorical net reclassification (0.08; p < 0.0001), and integrated discrimination (0.0105; p < 0.0001). Similar results were observed when NT-proBNP was added to the Reynolds Risk Score. CONCLUSIONS: In this multiethnic cohort of women with numerous CV events, NT-proBNP modestly improved measures of CVD risk prediction.
Authors: J David Curb; Anne McTiernan; Susan R Heckbert; Charles Kooperberg; Janet Stanford; Michael Nevitt; Karen C Johnson; Lori Proulx-Burns; Lisa Pastore; Michael Criqui; Sandra Daugherty Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Eric P Leip; Emelia J Benjamin; Peter W F Wilson; Patrice Sutherland; Torbjorn Omland; Ramachandran S Vasan Journal: Am J Cardiol Date: 2002-08-01 Impact factor: 2.778
Authors: Charlotte Kragelund; Bjørn Grønning; Lars Køber; Per Hildebrandt; Rolf Steffensen Journal: N Engl J Med Date: 2005-02-17 Impact factor: 91.245
Authors: Alan S Maisel; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Paul Clopton; Philippe G Steg; Arne Westheim; Catherine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough Journal: N Engl J Med Date: 2002-07-18 Impact factor: 91.245
Authors: Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone Journal: Circulation Date: 2004-07-13 Impact factor: 29.690
Authors: Saihari Sadanandan; Christopher P Cannon; Kasi Chekuri; Sabina A Murphy; Peter M Dibattiste; David A Morrow; James A de Lemos; Eugene Braunwald; C Michael Gibson Journal: J Am Coll Cardiol Date: 2004-08-04 Impact factor: 24.094
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan Journal: Circulation Date: 2004-02-10 Impact factor: 29.690
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Torbjorn Omland; Philip A Wolf; Ramachandran S Vasan Journal: N Engl J Med Date: 2004-02-12 Impact factor: 91.245
Authors: Emily S Lau; Samantha M Paniagua; James Sawalla Guseh; Vijeta Bhambhani; Markella V Zanni; Paul Courchesne; Asya Lyass; Martin G Larson; Daniel Levy; Jennifer E Ho Journal: J Am Coll Cardiol Date: 2019-09-24 Impact factor: 24.094
Authors: Stephen P Juraschek; Lara C Kovell; Lawrence J Appel; Edgar R Miller; Frank M Sacks; Robert H Christenson; Heather Rebuck; Alexander R Chang; Kenneth J Mukamal Journal: Ann Intern Med Date: 2020-05-19 Impact factor: 25.391
Authors: James A de Lemos; Colby R Ayers; Benjamin D Levine; Christopher R deFilippi; Thomas J Wang; W Gregory Hundley; Jarett D Berry; Stephen L Seliger; Darren K McGuire; Pamela Ouyang; Mark H Drazner; Matthew Budoff; Philip Greenland; Christie M Ballantyne; Amit Khera Journal: Circulation Date: 2017-03-30 Impact factor: 29.690
Authors: Pratyaksh K Srivastava; Aruna D Pradhan; Nancy R Cook; Paul M Ridker; Brendan M Everett Journal: Am J Cardiol Date: 2015-11-18 Impact factor: 2.778
Authors: Brendan M Everett; Tanja Zeller; Robert J Glynn; Paul M Ridker; Stefan Blankenberg Journal: Circulation Date: 2015-03-30 Impact factor: 29.690
Authors: Stefan Blankenberg; Veikko Salomaa; Nataliya Makarova; Francisco Ojeda; Philipp Wild; Karl J Lackner; Torben Jørgensen; Barbara Thorand; Annette Peters; Matthias Nauck; Astrid Petersmann; Erkki Vartiainen; Giovanni Veronesi; Paolo Brambilla; Simona Costanzo; Licia Iacoviello; Gerard Linden; John Yarnell; Christopher C Patterson; Brendan M Everett; Paul M Ridker; Jukka Kontto; Renate B Schnabel; Wolfgang Koenig; Frank Kee; Tanja Zeller; Kari Kuulasmaa Journal: Eur Heart J Date: 2016-05-12 Impact factor: 29.983
Authors: Stephen P Juraschek; Lara C Kovell; Lawrence J Appel; Edgar R Miller; Frank M Sacks; Alex R Chang; Robert H Christenson; Heather Rebuck; Kenneth J Mukamal Journal: J Am Coll Cardiol Date: 2021-06-01 Impact factor: 27.203